Abstract: The purpose of the present invention is to provide an agent for restoring a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function restoring ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-transporting receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-coupled receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-transporting receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the G-protein-coupled receptor rhodopsin.

Abstract: The present invention provides a screening method for searching a component inhibiting the PERK pathway and/or the ATF6 pathway, and by obtaining, by the screening method, an active ingredient inhibiting myopia progression without impairing normal growth of the eyeballs (emmetropization) in children, provides eyedrops and a composition containing the active ingredient. The problems are solved by eyedrops for inhibiting myopia progression in children containing, as an active ingredient, an inhibitor of the PERK (PKR-like endoplasmic reticulum kinase) pathway and/or the ATF6 (activating transcription factor 6) pathway. The problems are solved by a screening method for an inhibitor of myopia progression in children, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an index, change in a protein and/or a gene of the signal transduction system of PERK and/or ATF6.

Abstract: An object of the present invention is to provide a composition for preventing visual dysfunction caused by exposure to light, such as so-called blue light. The present invention provides a composition comprising a lactic acid bacterium as an active ingredient for use in suppressing or improving conditions caused by retinal inflammation resulting from light damage. Eye discomfort is an exemplary condition caused by retinal inflammation resulting from light damage.

Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.

Abstract: A device and a method for inhibiting thinning of a choroid. A choroidal thinning inhibiting device including a light source that emits violet light having a wavelength within a range from 360 nm to 400 nm, the choroidal thinning inhibiting device inhibiting thinning of a choroid by irradiation with the violet light. This device may further include a control mechanism that controls an irradiance and an irradiation time of the violet light, can be applied to ocular diseases selected from age-related macular degeneration, glaucoma, diabetic retinopathy, macular edema, eye strain, retinal vascular occlusion, triangle syndrome, central serous chorioretinopathy, retinitis pigmentosa, presbyopia, cataracts, and the like that are based on inadequate blood flow or reduced blood flow, and can be expected to prevent and treat such ocular diseases.

Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.

Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.

Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.

Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.

Abstract: An object of the present invention is to provide a composition for preventing visual dysfunction caused by exposure to light, such as so-called blue light. The present invention provides a composition comprising a lactic acid bacterium as an active ingredient for use in suppressing or improving conditions caused by retinal inflammation resulting from light damage. Eye discomfort is an exemplary condition caused by retinal inflammation resulting from light damage.

Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.

Abstract: An object of the present invention is to provide a composition for preventing visual dysfunction caused by exposure to light, such as so-called blue light. The present invention provides a composition comprising a lactic acid bacterium as an active ingredient for use in suppressing or improving conditions caused by retinal inflammation resulting from light damage. Eye discomfort is an exemplary condition caused by retinal inflammation resulting from light damage.

Abstract: Provided are a chimeric protein of two types of rhodopsins, an ion-transporting rhodopsin and a G protein-coupled receptor rhodopsin, and a nucleic acid encoding the same, for the prevention and suppression of progression of retinal diseases, the improvement in visual cognitive behavioral functions (e.g., improvement in light-dark determination functions, improvement in bright spot evading functions, and/or crisis avoidance functions), and the enhancement of visual functions (e.g., improvement in visual acuity). The present invention also provides a method for preventing or suppressing the progression of a disease, disorder or symptom of the retina, for improving a visual cognitive behavioral function (e.g., improvement in light-dark determination functions, improvement in bright spot evading functions, and/or crisis avoidance functions), or for enhancing visual functions (e.g.

Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.

Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.

Abstract: A device for supporting diagnosis has: a reception unit that is configured to receive a fundus image of a subject eye; an identification unit provided with a trained model that is configured to recognize, in the fundus image of the subject eye, an area of abnormality in blood circulation, wherein the model has been trained based upon an image of a fundus and an area of abnormality in blood circulation specified in a fluorescent angiography image of the fundus; and an output unit that is configured to output information relating to the area of abnormality in blood circulation recognized in the fundus image of the subject eye.

Abstract: A wavelength-selective transmissive glass has a light transmittance Tmore than 315 nm and 400 nm or less at a wavelength of more than 315 nm and 400 nm or less represented by the formula shown below of 1% or more in terms of a plate thickness of 6 mm and a light transmittance T315 nm or less at a wavelength of 315 nm or less represented by the formula shown below of 60% or less in terms of a plate thickness of 6 mm. Ak is a weighting factor at a wavelength k (nm) for calculating T (light transmittance) defined in ISO-9050:2003, and Tk is a transmittance at the wavelength k (nm) in terms of a plate thickness of 6 mm: Tmore than 315 nm and 400 nm or less=(?k=more than 315400Ak×Tk)/(?k=more than 315400Ak) T315 nm or less=(?k=300315Ak×Tk)/(?k=300315Ak).

Abstract: An optical element has a transmission spectrum characterized in that a local maximum falls within a wavelength region longer than 315 nm but shorter than or equal to 400 nm, a local minimum falls within a wavelength region longer than or equal to 380 nm but shorter than or equal to 500 nm, and the wavelength at the local maximum is shorter than the wavelength at the local minimum.

Abstract: The purpose of the present invention is to provide a myopia treatment device. A myopia treatment device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia. Or, the myopia treatment device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia.

Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.